FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma

Yussanne, P.; Leeuwen, Flora E. van; Cooke, Rosie; Broeks, Annegien; Enciso-Mora, Victor; Olver, Bianca; Lloyd, Amy; Russell, Nicola S.; Janus, Cécile P.M.; Ashworth, Alan; Houlston, Richard S.; Swerdlow, Anthony

doi:10.1182/blood-2011-10-383380

Cited by 29 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6][7][8] Best et al showed 2 variants at chromosome 6q21 to be associated with subsequent malignant neoplasm in survivors of HL treated with radiation therapy as children but not as adults. 6 Ma et al showed that genetic variation in FGFR2 influences breast cancer risk in HL patients treated with radiotherapy.…”

Section: Second Malignancymentioning

confidence: 99%

“…Further work on genetic susceptibility to developing late effects of treatment can help to guide initial treatment decision and allow targeted and tailored followup of survivors. 6,8 Additional research efforts on correlating radiation dosimetric parameters of specific organs with late effects would improve our understanding of the relationship between radiation dosevolume and long-term risks and guide future radiation treatment planning. 24,34 There are emerging data on an association between anthracyclines and, not just cardiac risk, but also solid tumors, and further follow-up is needed to confirm the findings.…”

Section: Future Directionsmentioning

confidence: 99%

“…6 Ma et al showed that genetic variation in FGFR2 influences breast cancer risk in HL patients treated with radiotherapy. 8 Leukemia. Earlier studies showed an increased leukemia risk with the use of MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) chemotherapy, and the use of large-field radiotherapy further contributes to the risk.…”

Section: Second Malignancymentioning

confidence: 99%

See 2 more Smart Citations

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Blood

View full text Add to dashboard Cite

Long-term survivors of Hodgkin lymphoma (HL) are at an increased risk for a range of late complications, with subsequent malignant neoplasm and cardiovascular disease representing the 2 leading causes of death in these patients. Raising awareness, close follow-up, and adoption of selected earlydetection and risk-reduction strategies may help to reduce the adverse impact of these late effects on patients. This chapter reviews known long-term complications of HL therapy, risk factors, and the timing of their occurrence. Where available, data on the efficacy of screening for selected late effects of HL are presented. Current evidence-based and consensus-based recommendations on follow-up of longterm HL survivors are also reviewed. As HL therapy evolves over time, late effects and implications on follow-up of patients treated in the contemporary era should be considered and opportunities for future research should be explored. (Blood. 2014; 124(23):3373-3379)

show abstract

Section: Second Malignancymentioning

confidence: 99%

Section: Future Directionsmentioning

confidence: 99%

Section: Second Malignancymentioning

confidence: 99%

See 1 more Smart Citation

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Blood

View full text Add to dashboard Cite

show abstract

“…1 These studies have a small number of patients that developed second malignancies, 49 and 59 patients, respectively. Underlying explanation for our findings, that a prior malignancy increases the risk of second malignancies in MM patients, could include genetic susceptibilities, [17][18][19][20][21][22][32][33][34][35] immunosuppression, [36][37][38] and therapy-related cancers. 12,13,39 We found MM patients with a prior cancer diagnosis to have an increased risk of developing hematological malignancy, melanoma, nonmelanoma skin cancer, and respiratory malignancy compared with MM patients who did not.…”

Section: Discussionmentioning

confidence: 99%

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Therefore, less pathogenic low-penetrance genetic susceptibility might be more important. Recent studies identified allelic variants in PRDM1 and FGFR2 to predispose Hodgkin lymphoma survivors to radiationinduced breast cancer (Best et al 2011, Ma et al 2012). …”

Section: Epidemiology and Host-related Risk Factorsmentioning

confidence: 99%

Risk factors for subsequent endocrine-related cancer in childhood cancer survivors

Wijnen¹,

Heuvel‐Eibrink²,

Medici³

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Long-term adverse health conditions, including secondary malignant neoplasms, are common in childhood cancer survivors. Although mortality attributable to secondary malignancies declined over the past decades, the risk for developing a solid secondary malignant neoplasm did not. Endocrine-related malignancies are among the most common secondary malignant neoplasms observed in childhood cancer survivors. In this systematic review, we describe risk factors for secondary malignant neoplasms of the breast and thyroid, since these are the most common secondary endocrine-related malignancies in childhood cancer survivors. Radiotherapy is the most important risk factor for secondary breast and thyroid cancer in childhood cancer survivors. Breast cancer risk is especially increased in survivors of Hodgkin lymphoma who received moderate-to high-dosed mantle field irradiation. Recent studies also demonstrated an increased risk after lowerdose irradiation in other radiation fields for other childhood cancer subtypes. Premature ovarian insufficiency may protect against radiation-induced breast cancer. Although evidence is weak, estrogen-progestin replacement therapy does not seem to be associated with an increased breast cancer risk in premature ovarian-insufficient childhood cancer survivors. Radiotherapy involving the thyroid gland increases the risk for secondary differentiated thyroid carcinoma, as well as benign thyroid nodules. Currently available studies on secondary malignant neoplasms in childhood cancer survivors are limited by short follow-up durations and assessed before treatment regimens. In addition, studies on risk-modifying effects of environmental and lifestyle factors are lacking. Risk-modifying effects of premature ovarian insufficiency and estrogen-progestin replacement therapy on radiation-induced breast cancer require further study. 23:6Review M Wijnen et al.Subsequent endocrine-related cancer risk in CCS

show abstract

FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma

Cited by 29 publications

References 23 publications

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study

Risk factors for subsequent endocrine-related cancer in childhood cancer survivors

Contact Info

Product

Resources

About